CDKN2A acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This interaction inhibits CDKs binding to cyclins D and phosphorylation of the retinoblastoma protein. Defects in CDKN2A are the cause of numerous cancers such as melanoma and astrocytoma.The synthetic peptide used to raise the antibody Cat. No. 200147 is selected from a sequence within the center region of human CDKN2A. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.